Ketamine treatment for depression is a specialist medical approach considered for some people whose symptoms have not improved sufficiently with other care. Research shows that intravenous ketamine can produce a rapid antidepressant effect, but benefit is not universal and may be short-lived.
The important questions are not only whether someone might feel better after treatment. They include how safely treatment can be delivered, how long improvement lasts, what happens if symptoms return and how ketamine fits within a complete mental health plan.
What is ketamine?
Ketamine is a medicine with established anesthetic uses. It affects signaling involving glutamate, including NMDA receptors, but its antidepressant mechanisms are still being investigated. An explanation involving brain plasticity should not be turned into a promise that treatment repairs the brain or permanently removes depression.
As the US Food and Drug Administration states, ketamine itself is not FDA-approved for a psychiatric disorder. Oxford Health NHS similarly describes its use for depression as off-label in the UK.
Off-label prescribing does not automatically mean inappropriate prescribing. It does mean that the rationale, evidence, uncertainties, consent and monitoring need to be explained clearly for the particular treatment and jurisdiction.
Ketamine and esketamine are not interchangeable
Ketamine contains two mirror-image forms of the molecule. Esketamine is one of those forms and is available as the branded nasal medicine Spravato, with specific authorizations and administration requirements.
The European Medicines Agency describes Spravato’s authorized use with an SSRI or SNRI for specified adults with treatment-resistant major depression. This does not make every ketamine infusion, nasal spray or oral preparation an authorized depression treatment.
The separate esketamine guide explains that distinction. Ask exactly which medicine and route are proposed rather than relying on the umbrella phrase ketamine therapy.
Who might be considered for assessment?
A clinician should establish the nature and severity of the depression and review previous treatments. Important details include whether medicines were tolerated, whether they were tried adequately and what psychological treatment or other support has been available.
The label treatment-resistant should not end the assessment. Physical illness, substance use, sleep problems, bipolar symptoms or a different diagnosis can affect the plan and may need attention first.
The depression treatment guide provides broader context. A specialist assessment should consider ketamine alongside alternatives, not assume that disappointing previous treatment makes it the inevitable next choice.
What does the research show?
In a randomised trial comparing a single ketamine infusion with midazolam, participants receiving ketamine had greater improvement in depression scores at 24 hours. The study supported a rapid effect while identifying the need for more information about durability and safety.
A later study of repeated and maintenance infusions found cumulative improvement and maintenance of benefit among responders during continued treatment. Its findings do not establish that indefinite treatment is necessary or effective for everyone.
A responsible discussion separates early response, remission and sustained recovery. Ask which outcome a quoted success rate describes, who was included and how many people did not benefit or stopped treatment.
How does ketamine compare with ECT?
The ELEKT-D randomised trial found intravenous ketamine non-inferior to ECT for the studied short-term treatment response in adults with treatment-resistant major depression without psychosis. The study was open-label and compared particular treatment schedules.
That result does not establish that ketamine should replace ECT for psychotic depression, catatonia, every severe presentation or every individual. It also cannot be applied automatically to oral or compounded nasal ketamine.
The ECT guide and TMS guide explain different medical approaches. Choosing between them requires attention to urgency, evidence, adverse effects and the person’s circumstances.
Preparation and medical screening
Explain your cardiovascular and neurological history, current medicines, previous reactions to treatment, substance use and any history of mania or psychosis. Pregnancy or plans for pregnancy also require a specific discussion.
The team should review physical and mental health risks, consent and practical support. An online questionnaire alone should not be treated as a complete medical assessment for a psychoactive treatment.
Ask for individual instructions about food, drink and medicines before an appointment. Do not stop prescribed medication or alter sedatives independently to prepare for ketamine; the treating clinicians need to coordinate those decisions.
What happens during an infusion?
Oxford Health’s treatment information describes intravenous administration in a clinical setting with staff present and a recovery period afterward. Exact arrangements differ between services and should be confirmed in advance.
During treatment, perception and the sense of time or connection with the body may change. Some people find this unsettling. Preparation should explain how to communicate distress and what staff will do if the experience becomes difficult.
A dramatic or pleasant subjective experience is not the same as a sustained antidepressant response. Treatment outcomes need to be reviewed after the immediate effects have passed.
Side effects and longer-term concerns
Oxford Health describes possible dissociation, dizziness, nausea, anxiety and changes in blood pressure or heart rate. Symptoms can worsen in some people, and an adverse experience deserves assessment rather than reassurance alone.
Repeated exposure also raises questions about tolerance, misuse, urinary problems and other potential harms. New urinary pain, unusual frequency, abdominal symptoms or concerning changes in thinking should be reported promptly.
The risks of heavy non-medical use cannot be equated directly with a monitored medical course, but neither should a prescription be used to imply that long-term harm is impossible. Discuss what is known and what remains uncertain.
Misuse, dependence and online products
Be open about previous substance difficulties or feeling drawn to use ketamine outside the agreed plan. Craving, increasing use or obtaining additional supplies are reasons to seek help, not to conceal the problem out of embarrassment.
The FDA has issued safety alerts concerning compounded ketamine products. A medicine ordered online is not equivalent to participating in a monitored clinical trial or attending a properly supervised service.
Do not obtain ketamine for self-treatment or reproduce a research protocol at home. The ketamine-related problems guide discusses support when use itself is causing harm.
Ketamine and suicidal thoughts
A randomised trial found a greater short-term reduction in suicidal thoughts with ketamine than with midazolam in adults with major depression. Reducing a symptom score does not prove prevention of suicide or remove the need for ongoing safety care.
Someone who cannot stay safe needs urgent local assessment, not a routine ketamine appointment or an online inquiry. A rapid-acting treatment must not be presented as a reason to delay emergency support.
Any treatment plan should explain who reviews changing risk and what happens between appointments. Improvement after one session should not lead to automatic withdrawal of other support.
Follow-up, relapse and psychological support
Agree how mood and functioning will be monitored after the initial course. If benefit fades, the team should review the balance of further treatment, adverse effects, practical burden and alternatives.
Supportive preparation or integration sessions may help a person discuss their experience, but the term ketamine-assisted psychotherapy covers varying models. Evidence for a drug treatment should not be presented as proof for every associated therapy package.
Medication review, psychological treatment and practical changes may remain important. There should be a plan for ongoing care even when ketamine is not continued.
Practical arrangements before booking
Confirm medical oversight, monitoring, recovery arrangements and emergency procedures. Ask about the total cost of assessment, treatment and follow-up, rather than comparing only the price of an infusion.
Arrange transport and support according to the treating team’s written instructions. Do not drive away after ketamine or assume that feeling more alert means judgment and coordination have fully recovered.
Consider how repeat appointments fit with work, caring responsibilities and where you live. Treatment should be feasible and coordinated, not dependent on repeatedly traveling without adequate support.
Frequently asked questions about ketamine for depression
Can ketamine work quickly?
Some clinical trials show improvement within a day, but not everyone responds and early benefit may fade. The question of sustained recovery is separate from how someone feels immediately after an infusion.
Is ketamine the same as Spravato?
No. Spravato contains esketamine and has specific regulatory indications and supervision requirements. Other ketamine preparations differ in composition, route and evidence and should not be treated as interchangeable.
Is the treatment experience always pleasant?
No. Altered perception or dissociation can be distressing. Discuss this before treatment and tell staff if you feel frightened or unwell. A difficult experience is not something you must endure to prove commitment.
Does ketamine replace my other treatment?
Not automatically. Any changes to medication, therapy or safety support need to be agreed with the relevant clinicians. Ketamine is considered within a broader plan, not as a reason to stop established care independently.
Will I need treatment indefinitely?
There is no universal answer. Continued treatment should depend on benefit, tolerability, risks and alternatives, with regular review. A fixed promise of permanent recovery or lifelong need would be inappropriate.
Can I treat myself with ketamine at home?
Do not obtain ketamine for self-treatment. Its psychoactive and medical risks require professional assessment. Any prescribed arrangement must follow the responsible clinician’s plan and applicable local requirements.
Discussing your next step
A clinical assessment can clarify the options for persistent depression. Contact VAYEMA to discuss your treatment history and appropriate next steps.
Sources and further reading
- Randomised ketamine and midazolam trial
- Repeated and maintenance ketamine study
- ELEKT-D: Ketamine compared with ECT
- Trial examining suicidal thoughts
- Oxford Health: Risks and benefits
- Oxford Health: Treatment and follow-up
- EMA: Spravato
- FDA: Compounding risk alerts
Related conditions and concerns
These links explain the wider care context. They are not a recommendation that this approach is suitable for everyone with the condition. Use the condition treatment guide to understand alternatives and the role of clinical assessment.